Short communication| Volume 339, 577115, February 15, 2020

Download started.


MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis

Published:November 20, 2019DOI:


      • MyMD1 (Isomyosmine) is a novel plant alkaloid with immunomodulatory properties.
      • MyMD1 inhibits activation of Th1 and Th17 cells in vitro.
      • MyMD1 ameliorates the course of EAE and decreases the effector cells in the brains of mice with EAE.


      Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.

      Graphical abstract

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bruck W.
        The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.
        J. Neurol. 2005; 252 (PubMed PMID: 16254699): v3-v9
        • Bruck W.
        • Stadelmann C.
        The spectrum of multiple sclerosis: new lessons from pathology.
        Curr. Opin. Neurol. 2005; 18 (PubMed PMID: 15891403): 221-224
        • Caturegli P.
        • De Remigis A.
        • Ferlito M.
        • Landek-Salgado M.A.
        • Iwama S.
        • Tzou S.C.
        • Ladenson P.W.
        Anatabine ameliorates experimental autoimmune thyroiditis.
        Endocrinology. 2012; 153 (PubMed PMID: 22807490): 4580-4587
        • Compston A.
        • Coles A.
        Multiple sclerosis.
        Lancet. 2008; 372 (PubMed PMID: 18970977): 1502-1517
        • Cushnie T.P.
        • Cushnie B.
        • Lamb A.J.
        Alkaloids: an overview of their antibacterial, antibiotic-enhancing and antivirulence activities.
        Int. J. Antimicrob. Agents. 2014; 44 (PubMed PMID: 25130096): 377-386
        • Dardalhon V.
        • Korn T.
        • Kuchroo V.K.
        • Anderson A.C.
        Role of Th1 and Th17 cells in organ-specific autoimmunity.
        J Autoimmun. 2008; 31 (PubMed PMID: 18502610; PMCID: PMC3178062): 252-256
        • Di Dalmazi G.
        • Chalan P.
        • Caturegli P.
        MYMD-1, a novel Immunometabolic regulator, ameliorates autoimmune thyroiditis via suppression of Th1 responses and TNF-alpha release.
        J. Immunol. 2019; 202 (PubMed PMID: 30674573): 1350-1362
        • Glenn J.D.
        • Smith M.D.
        • Xue P.
        • Chan-Li Y.
        • Collins S.
        • Calabresi P.A.
        • Horton M.R.
        • Whartenby K.A.
        CNS-targeted autoimmunity leads to increased influenza mortality in mice.
        J. Exp. Med. 2017; 214 (PubMed PMID: 28057805; PMCID: PMC5294848): 297-307
        • Glenn J.D.
        • Xue P.
        • Whartenby K.A.
        Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
        J. Neuroimmunol. 2018; 316 (PubMed PMID: 29274729): 7-16
        • Goldenberg M.M.
        Multiple sclerosis review.
        P T. 2012; 37 (PubMed PMID: 22605909; PMCID: PMC3351877): 175-184
        • Kister I.
        • Bacon T.E.
        • Chamot E.
        • Salter A.R.
        • Cutter G.R.
        • Kalina J.T.
        • Herbert J.
        Natural history of multiple sclerosis symptoms.
        Int. J. MS Care. 2013; 15 (PubMed PMID: 24453777; PMCID: PMC3883021): 146-158
        • Korn T.
        • Oukka M.
        • Kuchroo V.
        • Bettelli E.
        Th17 cells: effector T cells with inflammatory properties.
        Semin. Immunol. 2007; 19 (PubMed PMID: 18035554; PMCID: PMC2839934): 362-371
        • Li C.W.
        • Menconi F.
        • Osman R.
        • Mezei M.
        • Jacobson E.M.
        • Concepcion E.
        • David C.S.
        • Kastrinsky D.B.
        • Ohlmeyer M.
        • Tomer Y.
        Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis.
        J. Biol. Chem. 2016; 291 (PubMed PMID: 26703475; PMCID: PMC4759184): 4079-4090
        • Nizri E.
        • Irony-Tur-Sinai M.
        • Lory O.
        • Orr-Urtreger A.
        • Lavi E.
        • Brenner T.
        Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses.
        J. Immunol. 2009; 183 (PubMed PMID: 19846875): 6681-6688
        • O’Connor R.A.
        • Taams L.S.
        • Anderton S.M.
        Translational mini-review series on Th17 cells: CD4 T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation.
        Clin. Exp. Immunol. 2010; 159 (PubMed PMID: 19912249; PMCID: PMC2810382): 137-147
        • Orton S.M.
        • Herrera B.M.
        • Yee I.M.
        • Valdar W.
        • Ramagopalan S.V.
        • Sadovnick A.D.
        • Ebers G.C.
        • Canadian Collaborative Study G.
        Sex ratio of multiple sclerosis in Canada: a longitudinal study.
        Lancet Neurol. 2006; 5 (PubMed PMID: 17052660): 932-936
        • Rogosnitzky M.
        • Danks R.
        Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions.
        Pharmacol. Rep. 2011; 63 (PubMed PMID: 21602589): 337-347
        • Schmeltz L.R.
        • Blevins T.C.
        • Aronoff S.L.
        • Ozer K.
        • Leffert J.D.
        • Goldberg M.A.
        • Horowitz B.S.
        • Bertenshaw R.H.
        • Troya P.
        • Cohen A.E.
        • Lanier R.K.
        • Wright C.T.
        Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto’s) thyroiditis: a randomized controlled clinical trial.
        J. Clin. Endocrinol. Metab. 2014; 99 (PubMed PMID: 24178792; PMCID: PMC3928963): E137-E142
        • Skarica M.
        • Wang T.
        • McCadden E.
        • Kardian D.
        • Calabresi P.A.
        • Small D.
        • Whartenby K.A.
        Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.
        J. Immunol. 2009; 182 (PubMed PMID: 19299717; PMCID: PMC3727416): 4192-4199
        • Tasaka Y.
        • Yasunaga D.
        • Kiyoi T.
        • Tanaka M.
        • Tanaka A.
        • Suemaru K.
        • Araki H.
        Involvement of stimulation of alpha7 nicotinic acetylcholine receptors in the suppressive effect of tropisetron on dextran sulfate sodium-induced colitis in mice.
        J. Pharmacol. Sci. 2015; 127 (PubMed PMID: 25837923): 275-283
        • Ziegler J.
        • Facchini P.J.
        Alkaloid biosynthesis: metabolism and trafficking.
        Annu. Rev. Plant Biol. 2008; 59 (PubMed PMID: 18251710): 735-769